Janux Therapeutics (JANX) Competitors $33.20 +0.65 (+2.00%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$33.02 -0.18 (-0.53%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. LNTH, RVMD, BBIO, LEGN, TGTX, TLX, BPMC, SRPT, AXSM, and NUVLShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Janux Therapeutics (NASDAQ:JANX) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, community ranking, institutional ownership, media sentiment and risk. Is JANX or LNTH more profitable? Lantheus has a net margin of 28.57% compared to Janux Therapeutics' net margin of -463.91%. Lantheus' return on equity of 44.29% beat Janux Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux Therapeutics-463.91% -10.47% -9.86% Lantheus 28.57%44.29%23.52% Do insiders and institutionals have more ownership in JANX or LNTH? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer JANX or LNTH? Lantheus received 298 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Janux Therapeutics an outperform vote while only 66.02% of users gave Lantheus an outperform vote. CompanyUnderperformOutperformJanux TherapeuticsOutperform Votes4470.97% Underperform Votes1829.03% LantheusOutperform Votes34266.02% Underperform Votes17633.98% Do analysts prefer JANX or LNTH? Janux Therapeutics presently has a consensus target price of $95.25, suggesting a potential upside of 186.90%. Lantheus has a consensus target price of $129.43, suggesting a potential upside of 24.05%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Janux Therapeutics is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09Lantheus 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, JANX or LNTH? Janux Therapeutics has a beta of 3.27, indicating that its share price is 227% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Which has better earnings & valuation, JANX or LNTH? Lantheus has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10.59M185.53-$58.29M-$1.28-25.94Lantheus$1.53B4.66$326.66M$4.3723.88 Does the media prefer JANX or LNTH? In the previous week, Lantheus had 9 more articles in the media than Janux Therapeutics. MarketBeat recorded 23 mentions for Lantheus and 14 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.43 beat Lantheus' score of 1.25 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 16 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLantheus beats Janux Therapeutics on 10 of the 19 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.93B$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-28.387.4422.4818.48Price / Sales185.53242.70395.93103.60Price / CashN/A65.8538.1834.62Price / Book4.456.516.774.25Net Income-$58.29M$143.21M$3.22B$248.23M7 Day Performance3.52%1.98%1.47%0.89%1 Month Performance23.83%6.89%3.99%3.53%1 Year Performance-42.95%-2.52%16.15%5.08% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics3.018 of 5 stars$33.20+2.0%$95.25+186.9%-41.8%$1.93B$10.59M-28.3830Upcoming EarningsNews CoveragePositive NewsLNTHLantheus3.9823 of 5 stars$100.62-0.7%$129.43+28.6%+56.8%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.7636 of 5 stars$36.56-0.5%$66.67+82.3%+8.3%$6.80B$742,000.00-10.18250Upcoming EarningsAnalyst ForecastPositive NewsBBIOBridgeBio Pharma4.5498 of 5 stars$33.51-1.1%$53.00+58.2%+49.7%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageLEGNLegend Biotech2.6303 of 5 stars$32.24-1.7%$79.00+145.0%-20.1%$5.92B$627.24M-33.941,070Positive NewsTGTXTG Therapeutics3.3378 of 5 stars$36.97-3.5%$40.67+10.0%+233.2%$5.81B$329.00M-369.66290Upcoming EarningsPositive NewsGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownBPMCBlueprint Medicines2.5598 of 5 stars$84.18-0.6%$124.95+48.4%-2.0%$5.38B$508.82M-77.94640Analyst ForecastPositive NewsSRPTSarepta Therapeutics4.678 of 5 stars$55.23+2.7%$158.70+187.3%-50.7%$5.36B$1.90B44.18840AXSMAxsome Therapeutics4.8386 of 5 stars$103.00-1.4%$169.80+64.9%+52.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsNUVLNuvalent1.891 of 5 stars$69.95-2.4%$115.50+65.1%+11.4%$5.01BN/A-20.1640Upcoming EarningsPositive News Related Companies and Tools Related Companies LNTH Competitors RVMD Competitors BBIO Competitors LEGN Competitors TGTX Competitors TLX Competitors BPMC Competitors SRPT Competitors AXSM Competitors NUVL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
